Cell-based immunotherapy of glioblastoma multiforme.
Cell-based immunotherapy of glioblastoma multiforme.
复制标题
DOI：
10.3892/ol.2022.13253
复制
发表时间：
2022-04
期刊：
影响因子：
2.9
通讯作者：
Bryukhovetskiy I
中科院分区：
文献类型：
--
作者：
Bryukhovetskiy I
多形性胶质母细胞瘤（GBM）是最具侵袭性和致命性的原发性胶质脑肿瘤。它具有不利的预后和相对无效的治疗方案，患者的中位生存期约为15个月。肿瘤对治疗的抗性与其癌症干细胞（CSC）有关。目前，还没有药物或技术能够完全根除CSC，免疫疗法（IT）只能延长患者的生命。本综述旨在研究与免疫抑制相关问题的系统解决方案，例如无效IT和为CSC创造最佳条件以实现其致命潜力。本综述还探讨了局部免疫抑制治疗的主要方法，并强调了相关的缺点。此外，新的治疗方案和目标的消除和调节CSC与适应性和主动IT进行了讨论。还总结了TGF-β抑制剂的拮抗剂、免疫检查点和其他靶向药物。正常造血干细胞（HSC）在GBM的情况下，系统性免疫抑制发展的机制中的作用进行了分析，并讨论了HSC与癌细胞相互作用过程中的潜在重编程。此外，本综述强调了上述相互作用在肿瘤过程中免疫耐受和免疫系统失活的发展中的重要性。讨论了解决供体造血干细胞移植过程中系统性免疫抑制问题的可能性。
Glioblastoma multiforme (GBM) is the most aggressive and lethal primary glial brain tumor. It has an unfavorable prognosis and relatively ineffective treatment protocols, with the median survival of patients being ~15 months. Tumor resistance to treatment is associated with its cancer stem cells (CSCs). At present, there is no medication or technologies that have the ability to completely eradicate CSCs, and immunotherapy (IT) is only able to prolong the patient's life. The present review aimed to investigate systemic solutions for issues associated with immunosuppression, such as ineffective IT and the creation of optimal conditions for CSCs to fulfill their lethal potential. The present review also investigated the main methods involved in local immunosuppression treatment, and highlighted the associated disadvantages. In addition, novel treatment options and targets for the elimination and regulation of CSCs with adaptive and active IT are discussed. Antagonists of TGF-β inhibitors, immune checkpoints and other targeted medication are also summarized. The role of normal hematopoietic stem cells (HSCs) in the mechanisms underlying systemic immune suppression development in cases of GBM is analyzed, and the potential reprogramming of HSCs during their interaction with cancer cells is discussed. Moreover, the present review emphasizes the importance of the aforementioned interactions in the development of immune tolerance and the inactivation of the immune system in neoplastic processes. The possibility of solving the problem of systemic immunosuppression during transplantation of donor HSCs is discussed.
登录
查看更多内容
影响因子：
37.3
作者：
Beier D;Schulz JB;Beier CP
通讯作者：
Beier CP
影响因子：
4.1
作者：
Bostian AC;Maddukuri L;Reed MR;Savenka T;Hartman JH;Davis L;Pouncey DL;Miller GP;Eoff RL
通讯作者：
Eoff RL
影响因子：
15.9
作者：
Blumenthal, Deborah T.;Gorlia, Thierry;Stupp, Roger
通讯作者：
Stupp, Roger
影响因子：
6.4
作者：
Authier, Astrid;Farrand, Kathryn J.;Hermans, Ian F.
通讯作者：
Hermans, Ian F.
影响因子：
8.8
作者：
Affinito, Alessandra;Quintavalle, Cristina;Condorelli, Gerolama
通讯作者：
Condorelli, Gerolama